Stock Market

by David Haggith The state’s new ‘Ethnic Studies Model Curriculum’ extends the left’s cultural dominance of California’s public education system, and seeks to destroy the ‘Christianity, capitalism and racism’ white settlers brought to America. The Department of Education in California – where else? – has approved a 900-page “Ethnic Studies Model Curriculum” designed to “decolonize”
0 Comments
APi Group Corporation, a commercial life safety solutions and industrial specialty services provider, reported better-than-expected 4Q earnings. However, adjusted revenues came in below expectations, impacted by the pandemic. APi Group (APG) reported 4Q adjusted earnings of $0.34 per share that surpassed analysts’ expectations of $0.31 but declined 5.6% year-over-year. Meanwhile, adjusted net revenues of $874
0 Comments
by Jim Quinn The riots and pandemonium in Miami are being blamed on spring breakers. Looking at the photos below, I wonder what colleges these “youngsters” are from. They seem to be fine upstanding citizens. It must be the police fault. There seems to be some sort of common denominator, but I can’t put my
0 Comments
 By Chris Black All of Wall Street belongs in prison. Life in Clown World has never been stranger.  This article caught my attention yesterday:  Tesla shares are up about 5% in pre-market trading Monday after ARK Invest’s Cathie Wood released a “new and improved” price target on the company of $3,000 per share at the
0 Comments
IDEAYA Biosciences, a synthetic lethality-focused precision medicine oncology company, reported a smaller-than-expected loss in the fourth quarter and outpaced analysts’ expectations for revenues. IDEAYA (IDYA) incurred a loss of $0.18 per share in 4Q, compared to the loss of $0.53 recorded in the prior-year quarter. Analysts were expecting the company to report a loss of
0 Comments
Bristol Myers Squibb, a biopharmaceutical company, announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for mavacamten, an investigational, novel, oral, allosteric modulator of cardiac myosin. The drug is designed for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Bristol Myers Squibb’s (BMY) Cardiovascular Development Senior VP Roland
0 Comments
Take a look at some of the biggest movers in the premarket: AstraZeneca (AZN) – The drugmaker said a U.S. study showed its Covid-19 vaccine had 79% efficacy in preventing symptomatic illness, 100% effectiveness against critical disease and hospitalization, and did not pose a higher risk of blood clots. AstraZeneca shares gained 2.2% in premarket
0 Comments
Given that its business thrived rather than struggled during the worst of the COVID-19 pandemic, Domino’s Pizza (DPZ) stock delivered a solid performance during 2020. Last March, when markets cratered as the coronavirus spread, Domino’s held up reasonably well. Sure, it saw a brief decline during the market-wide sell-off, but already coming off of a
0 Comments
Widely recognized for its leading real-time non-structured data search capabilities, Elastic N.V. (ESTC) counts companies such as Uber (UBER), Lyft (LYFT), and Match Group (MTCH) as customers. Despite the ongoing pandemic, Elastic put up some pretty impressive numbers in Q3’21, with year-over-year revenue growth of 39% and a net expansion rate of 130%. Given that the business
0 Comments
Sometimes, popular sentiment fuels a market boom, and nowhere is that more evident than in the legal marijuana industry. However, cannabis remains illegal in the US at the Federal level, rendering the various state-level legalization regimes a patchwork of disconnected policies. Still, there is hope that the current Congress may pursue a Federal legalization bill
0 Comments
A Five Below location. John Greim | LightRocket | Getty Images Check out the companies making headlines after the bell on Wednesday: Five Below – The discount retailer’s shares ticked up 6% after the company’s fourth-quarter results topped Wall Street analyst expectations. Five Below reported earnings per share of $2.20 on revenue of $859 million.
0 Comments